Welcome!

News Feed Item

Bone Cancer Global Clinical Trials Review, H1, 2014

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Bone Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/bone_cancer_global_clinical_trials_review_h1_2014.html

Bone Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Bone Cancer Global Clinical Trials Review, H1, 2014" provides data on the Bone Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bone Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bone Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Bone Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Bone Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Bone Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Bone Cancer 25
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Bone Cancer Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Bone Cancer 37
Jan 03, 2014: Eleison Announces Achievement of Enrollment Milestone in its Phase II Trial of ILC for Pediatric Bone Cancer 37
Oct 22, 2012: Eleison Enrolls First Patient In Phase II Trial Of Cisplatin For Pediatric Bone Cancer 37
Aug 07, 2012: Philips And Celsion Announce FDA Clearance To Commence Phase II Study Of ThermoDox And MR-Guided HIFU In Bone Cancer 37
Mar 02, 2012: Niiki Pharma To Begin Phase I Trial Of NKP-2235 38
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 38
Clinical Trial Profiles 40
Clinical Trial Overview of Top Companies 40
Novartis AG 40
Clinical Trial Overview of Novartis AG 40
F. Hoffmann-La Roche Ltd. 46
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 46
Amgen Inc. 48
Clinical Trial Overview of Amgen Inc. 48
Bayer AG 50
Clinical Trial Overview of Bayer AG 50
Takeda Pharmaceutical Company Limited 52
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 52
Merck & Co., Inc. 53
Clinical Trial Overview of Merck & Co., Inc. 53
Pfizer Inc. 54
Clinical Trial Overview of Pfizer Inc. 54
AstraZeneca PLC 55
Clinical Trial Overview of AstraZeneca PLC 55
Eli Lilly and Company 56
Clinical Trial Overview of Eli Lilly and Company 56
Algeta ASA 57
Clinical Trial Overview of Algeta ASA 57
Clinical Trial Overview of Top Institutes / Government 58
National Cancer Institute 58
Clinical Trial Overview of National Cancer Institute 58
Children's Oncology Group 67
Clinical Trial Overview of Children's Oncology Group 67
The University of Texas M. D. Anderson Cancer Center 70
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 70
Memorial Sloan Kettering Cancer Center 72
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 72
Massachusetts General Hospital 74
Clinical Trial Overview of Massachusetts General Hospital 74
European Organization for Research and Treatment of Cancer 75
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 75
Southwest Oncology Group 76
Clinical Trial Overview of Southwest Oncology Group 76
University Health Network 77
Clinical Trial Overview of University Health Network 77
Stanford University 78
Clinical Trial Overview of Stanford University 78
Five Key Clinical Profiles 79
Appendix 180
Abbreviations 180
Definitions 180
Research Methodology 181
Secondary Research 181
About GlobalData 182
Contact Us 182
Disclaimer 182
Source 183

List of Tables

Bone Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Bone Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Bone Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Bone Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Bone Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Bone Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Bone Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Bone Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Bone Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Bone Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Bone Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Bone Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Bone Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Bone Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Bone Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Bone Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Bone Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Bone Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Bone Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Bone Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 40
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 46
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 48
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 50
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 52
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 53
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 54
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 55
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 56
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Algeta ASA, 2014* 57
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 58
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014* 67
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 70
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 72
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 74
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 75
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 76
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2014* 77
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 78

List of Figures

Bone Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Bone Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Bone Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Bone Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Bone Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Bone Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Bone Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Bone Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Bone Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Bone Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Bone Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Bone Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Bone Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Bone Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Bone Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Bone Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Bone Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 181

Read the full report:
Bone Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/bone_cancer_global_clinical_trials_review_h1_2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
Ovum, a leading technology analyst firm, has published an in-depth report, Ovum Decision Matrix: Selecting a DevOps Release Management Solution, 2016–17. The report focuses on the automation aspects of DevOps, Release Management and compares solutions from the leading vendors.
"Avere Systems is a hybrid cloud solution provider. We have customers that want to use cloud storage and we have customers that want to take advantage of cloud compute," explained Rebecca Thompson, VP of Marketing at Avere Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
"We formed Formation several years ago to really address the need for bring complete modernization and software-defined storage to the more classic private cloud marketplace," stated Mark Lewis, Chairman and CEO of Formation Data Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
Large scale deployments present unique planning challenges, system commissioning hurdles between IT and OT and demand careful system hand-off orchestration. In his session at @ThingsExpo, Jeff Smith, Senior Director and a founding member of Incenergy, will discuss some of the key tactics to ensure delivery success based on his experience of the last two years deploying Industrial IoT systems across four continents.
There will be new vendors providing applications, middleware, and connected devices to support the thriving IoT ecosystem. This essentially means that electronic device manufacturers will also be in the software business. Many will be new to building embedded software or robust software. This creates an increased importance on software quality, particularly within the Industrial Internet of Things where business-critical applications are becoming dependent on products controlled by software. Qua...
SYS-CON Events has announced today that Roger Strukhoff has been named conference chair of Cloud Expo and @ThingsExpo 2016 Silicon Valley. The 19th Cloud Expo and 6th @ThingsExpo will take place on November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. "The Internet of Things brings trillions of dollars of opportunity to developers and enterprise IT, no matter how you measure it," stated Roger Strukhoff. "More importantly, it leverages the power of devices and the Interne...
Machine Learning helps make complex systems more efficient. By applying advanced Machine Learning techniques such as Cognitive Fingerprinting, wind project operators can utilize these tools to learn from collected data, detect regular patterns, and optimize their own operations. In his session at 18th Cloud Expo, Stuart Gillen, Director of Business Development at SparkCognition, discussed how research has demonstrated the value of Machine Learning in delivering next generation analytics to imp...
Most organizations prioritize data security only after their data has already been compromised. Proactive prevention is important, but how can you accomplish that on a small budget? Learn how the cloud, combined with a defense and in-depth approach, creates efficiencies by transferring and assigning risk. Security requires a multi-defense approach, and an in-house team may only be able to cherry pick from the essential components. In his session at 19th Cloud Expo, Vlad Friedman, CEO/Founder o...
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. Commvault can ensure protection, access and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his general session at 18th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Part...
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
With over 720 million Internet users and 40–50% CAGR, the Chinese Cloud Computing market has been booming. When talking about cloud computing, what are the Chinese users of cloud thinking about? What is the most powerful force that can push them to make the buying decision? How to tap into them? In his session at 18th Cloud Expo, Yu Hao, CEO and co-founder of SpeedyCloud, answered these questions and discussed the results of SpeedyCloud’s survey.
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...